Among the DHODH inhibitors, MEDS433 and compound 4, with a decorated aryloxyaryl moiety in place of the biphenyl scaffold, showed differentiating effects on AML THP1 cells, which were superior to those of brequinar and enhanced by dipyridamole, via inhibition of pyrimidine supply, due to blockade of hENT1/2. This evidence concerns the gene SLC29A1 and acute myeloid leukemia.